Time to get in?_老虎社区_美港股上老虎

Jeffdad
2021-08-12

Time to get in?

Why Moderna Stock Crashed Today<blockquote>为什么Moderna股票今天暴跌</blockquote>

What happened Shares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulat

Why Moderna Stock Crashed Today<blockquote>为什么Moderna股票今天暴跌</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":895677704,"tweetId":"895677704","gmtCreate":1628743672708,"gmtModify":1631885101612,"author":{"id":3582785880297802,"idStr":"3582785880297802","authorId":3582785880297802,"authorIdStr":"3582785880297802","name":"Jeffdad","avatar":"https://static.tigerbbs.com/55fc04cec1892dd2d910600d9087116b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Time to get in?</body></html>","htmlText":"<html><head></head><body>Time to get in?</body></html>","text":"Time to get in?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/895677704","repostId":1153877356,"repostType":4,"repost":{"id":"1153877356","kind":"news","pubTimestamp":1628738808,"share":"https://www.laohu8.com/m/news/1153877356?lang=zh_CN&edition=full","pubTime":"2021-08-12 11:26","market":"us","language":"en","title":"Why Moderna Stock Crashed Today<blockquote>为什么Moderna股票今天暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1153877356","media":"The motley fool","summary":"What happened\nShares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulat","content":"What happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.<blockquote>本公司之股份现代在欧洲药品监管机构提供新冠肺炎疫苗安全更新后，（纳斯达克：MRNA）周三暴跌15.6%。</blockquote> So what<blockquote>那又怎样</blockquote> The European <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> Agency (EMA) is studying three new conditions reported by a small number of people who received mRNA COVID-19 vaccines provided by Moderna and<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>.<blockquote>欧洲人<a href=\"https://laohu8.com/S/MDCO\">药品</a>机构（EMA）正在研究少数接种Moderna和<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>.</blockquote> These conditions include:<blockquote>这些条件包括：</blockquote> <ul> <li>Erythema multiforme, an allergic skin reaction.</li> <li>Glomerulonephritis, or kidney inflammation.</li> <li>Nephrotic syndrome, a renal disorder.</li> </ul> The EMA is assessing whether these conditions could be possible side effects of the vaccines.<blockquote><ul><li>多形性红斑，一种过敏性皮肤反应。</li><li>肾小球肾炎，或肾脏炎症。</li><li>肾病综合征，一种肾脏疾病。</li></ul>EMA正在评估这些情况是否可能是疫苗的副作用。</blockquote> The information was provided as part of ongoing safety updates the EMA regularly delivers to the public. The EMA did not recommend any changes to the product information displayed on the labels of these vaccines.<blockquote>该信息是EMA定期向公众提供的持续安全更新的一部分。EMA不建议对这些疫苗标签上显示的产品信息进行任何更改。</blockquote> Now what<blockquote>现在怎么办</blockquote> Analysts had already raised concerns that Moderna's stock price had risen too far, too fast.<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>analyst Geoff Meacham said on Tuesday that Moderna's nearly $200 billion marketvaluationwas \"ridiculous\" and \"unjustifiable on a fundamental basis.\" Meacham argued that to be worth that much, Moderna would need to deliver between 1 billion and 1.5 billion doses of its coronavirus vaccine each year through 2038. Additionally, Moderna's entire pipeline of experimental drugs would need to prove successful and generate total peak sales of $30 billion.<blockquote>分析师已经对Moderna股价上涨过快、过快表示担忧。<a href=\"https://laohu8.com/S/BAC\">美国银行</a>分析师Geoff Meacham周二表示，Moderna近2000亿美元的市场估值“荒谬”且“从根本上来说不合理”。米查姆认为，要达到如此高的价值，Moderna需要在2038年之前每年提供10亿至15亿剂冠状病毒疫苗。此外，Moderna的整个实验药物管道需要被证明是成功的，并产生300亿美元的总峰值销售额。</blockquote> Meacham believes those two assumptions are highly unlikely, so he repeated his underperform rating on Moderna's stock and $115 price forecast for its shares. Even after today's plunge, Meacham's price target is still 70% below the stock's current price near $385.<blockquote>Meacham认为这两个假设的可能性极小，因此他重申了对Moderna股票的跑输评级和115美元的股价预测。即使在今天的暴跌之后，Meacham的目标价仍比该股目前385美元附近的价格低70%。</blockquote> Today's news and Meacham's warning appear to have driven many investors to take profits and sell their shares in Moderna.<blockquote>今天的消息和米查姆的警告似乎促使许多投资者获利了结并出售他们在Moderna的股票。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Crashed Today<blockquote>为什么Moderna股票今天暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Crashed Today<blockquote>为什么Moderna股票今天暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe motley fool2021-08-12 11:26\n\n</h4>\n</header>\n<article>\nWhat happened<blockquote>发生了什么</blockquote> Shares of&nbsp;Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.<blockquote>本公司之股份现代在欧洲药品监管机构提供新冠肺炎疫苗安全更新后，（纳斯达克：MRNA）周三暴跌15.6%。</blockquote> So what<blockquote>那又怎样</blockquote> The European <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> Agency (EMA) is studying three new conditions reported by a small number of people who received mRNA COVID-19 vaccines provided by Moderna and<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>.<blockquote>欧洲人<a href=\"https://laohu8.com/S/MDCO\">药品</a>机构（EMA）正在研究少数接种Moderna和<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>.</blockquote> These conditions include:<blockquote>这些条件包括：</blockquote> <ul> <li>Erythema multiforme, an allergic skin reaction.</li> <li>Glomerulonephritis, or kidney inflammation.</li> <li>Nephrotic syndrome, a renal disorder.</li> </ul> The EMA is assessing whether these conditions could be possible side effects of the vaccines.<blockquote><ul><li>多形性红斑，一种过敏性皮肤反应。</li><li>肾小球肾炎，或肾脏炎症。</li><li>肾病综合征，一种肾脏疾病。</li></ul>EMA正在评估这些情况是否可能是疫苗的副作用。</blockquote> The information was provided as part of ongoing safety updates the EMA regularly delivers to the public. The EMA did not recommend any changes to the product information displayed on the labels of these vaccines.<blockquote>该信息是EMA定期向公众提供的持续安全更新的一部分。EMA不建议对这些疫苗标签上显示的产品信息进行任何更改。</blockquote> Now what<blockquote>现在怎么办</blockquote> Analysts had already raised concerns that Moderna's stock price had risen too far, too fast.<a href=\"https://laohu8.com/S/BAC\">Bank of America</a>analyst Geoff Meacham said on Tuesday that Moderna's nearly $200 billion marketvaluationwas \"ridiculous\" and \"unjustifiable on a fundamental basis.\" Meacham argued that to be worth that much, Moderna would need to deliver between 1 billion and 1.5 billion doses of its coronavirus vaccine each year through 2038. Additionally, Moderna's entire pipeline of experimental drugs would need to prove successful and generate total peak sales of $30 billion.<blockquote>分析师已经对Moderna股价上涨过快、过快表示担忧。<a href=\"https://laohu8.com/S/BAC\">美国银行</a>分析师Geoff Meacham周二表示，Moderna近2000亿美元的市场估值“荒谬”且“从根本上来说不合理”。米查姆认为，要达到如此高的价值，Moderna需要在2038年之前每年提供10亿至15亿剂冠状病毒疫苗。此外，Moderna的整个实验药物管道需要被证明是成功的，并产生300亿美元的总峰值销售额。</blockquote> Meacham believes those two assumptions are highly unlikely, so he repeated his underperform rating on Moderna's stock and $115 price forecast for its shares. Even after today's plunge, Meacham's price target is still 70% below the stock's current price near $385.<blockquote>Meacham认为这两个假设的可能性极小，因此他重申了对Moderna股票的跑输评级和115美元的股价预测。即使在今天的暴跌之后，Meacham的目标价仍比该股目前385美元附近的价格低70%。</blockquote> Today's news and Meacham's warning appear to have driven many investors to take profits and sell their shares in Moderna.<blockquote>今天的消息和米查姆的警告似乎促使许多投资者获利了结并出售他们在Moderna的股票。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/08/11/why-moderna-stock-crashed-today/\">The motley fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/11/why-moderna-stock-crashed-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153877356","content_text":"What happened\nShares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.\nSo what\nThe European Medicines Agency (EMA) is studying three new conditions reported by a small number of people who received mRNA COVID-19 vaccines provided by Moderna andPfizer.\nThese conditions include:\n\nErythema multiforme, an allergic skin reaction.\nGlomerulonephritis, or kidney inflammation.\nNephrotic syndrome, a renal disorder.\n\nThe EMA is assessing whether these conditions could be possible side effects of the vaccines.\nThe information was provided as part of ongoing safety updates the EMA regularly delivers to the public. The EMA did not recommend any changes to the product information displayed on the labels of these vaccines.\nNow what\nAnalysts had already raised concerns that Moderna's stock price had risen too far, too fast.Bank of Americaanalyst Geoff Meacham said on Tuesday that Moderna's nearly $200 billion marketvaluationwas \"ridiculous\" and \"unjustifiable on a fundamental basis.\" Meacham argued that to be worth that much, Moderna would need to deliver between 1 billion and 1.5 billion doses of its coronavirus vaccine each year through 2038. Additionally, Moderna's entire pipeline of experimental drugs would need to prove successful and generate total peak sales of $30 billion.\nMeacham believes those two assumptions are highly unlikely, so he repeated his underperform rating on Moderna's stock and $115 price forecast for its shares. Even after today's plunge, Meacham's price target is still 70% below the stock's current price near $385.\nToday's news and Meacham's warning appear to have driven many investors to take profits and sell their shares in Moderna.","news_type":1,"symbols_score_info":{"BAC":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3003,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["TWX","TIME"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}